Medtronic, Beta Bionics and Tandem Diabetes Care showcased planned patch pumps at the conference, while Senseonics shared ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Type 2 diabetes is a long-term condition where the body can’t use insulin properly, causing blood sugar levels to stay too ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

A strategy of time-restricted eating with energy restriction and intermittent energy restriction alone both conferred ...

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

Key Takeaways A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial saysEcnoglutide helped patients lose more than 15% of their body weightNearly 93% of clinical trial ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...